Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice
Open Access
- 18 September 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1076
Abstract
Multiple gene therapy trials are occurring for a variety of ophthalmic diseases around the world. The safety of gene therapy in the eye has been established, and the next step is to reliably assess efficacy. This is primarily done through the use of imaging techniques and visual function measures. Standardized visual function assessments, however, were originally developed for a clinical setting and may not be suitable for detecting and quantifying therapeutic changes. This scoping review takes a comprehensive look at current practice in terms of the outcome measures defined at trial registration. These were compared to the outcome measures reported in the literature. All published trials reported the pre-registered primary outcome measure. A range of additional secondary outcomes were reported that were not originally planned. Gaps in gene therapy assessment exist and further discussion are required to find a way forward, particularly as more conditions progress to phase 2 and 3 trials. Several factors impacting on trial design and outcome measure choice are discussed.Keywords
This publication has 48 references indexed in Scilit:
- Three-Year Follow-up after Unilateral Subretinal Delivery of Adeno-Associated Virus in Patients with Leber Congenital Amaurosis Type 2Ophthalmology, 2013
- Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 MutationsArchives of Ophthalmology (1950), 2012
- The human visual cortex responds to gene therapy–mediated recovery of retinal functionJournal of Clinical Investigation, 2011
- Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 YearHuman Gene Therapy, 2009
- Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Optical coherence tomography: a review of clinical development from bench to bedsideJournal of Biomedical Optics, 2007
- Psychometric properties of vision‐related quality of life questionnaires: a systematic reviewOphthalmic and Physiological Optics, 2004